Stockscreener 앱 받기
10.57%
시장 영업 전:
전일 마감가:
$3.50
열려 있는:
$3.415
하루 거래량:
18.98M
Relative Volume:
7.30
시가총액:
$530.44M
수익:
$409.00K
순이익/손실:
$-101.35M
주가수익비율:
-2.3598
EPS:
-1.64
순현금흐름:
$-71.49M
1주 성능:
-44.64%
1개월 성능:
-28.73%
6개월 성능:
-46.32%
1년 성능:
-41.80%
1일 변동 폭
$3.30
$4.04
1주일 범위
$2.90
$7.73
52주 변동 폭
$2.90
$11.16
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
ALT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.87 | 530.44M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
Altimmune Announces Multiple Presentations at Upcoming American - GuruFocus
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions - The Manila Times
Breakthrough GLP-1/Glucagon Drug Pemvidutide Reveals Multiple Cardiometabolic Benefits in New Clinical Data - Stock Titan
Kalkine : Altimmune’s Role in NASDAQ Composite Amid Biotech Sector Momentum - Kalkine Media
Altimmune, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire
Two Sigma Advisers LP Sells 22,700 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Nuveen Asset Management LLC Has $1.56 Million Stock Position in Altimmune, Inc. (NASDAQ:ALT) - Defense World
BNP Paribas Financial Markets Sells 33,984 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Stifel analysts reaffirm Altimmune stock rating with $18 price target By Investing.com - Investing.com South Africa
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential - Seeking Alpha
Stifel analysts reaffirm Altimmune stock rating with $18 price target - Investing.com India
Altimmune, Inc. (NASDAQ:ALT) Shares Bought by ProShare Advisors LLC - Defense World
Altimmune, Inc. (NASDAQ:ALT) Stock Holdings Increased by Millennium Management LLC - Defense World
Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire
Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. (NASDAQ:ALT) Shares Bought by Deutsche Bank AG - Defense World
Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com India
Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook - Investing.com
FY2029 EPS Estimate for Altimmune Decreased by Analyst - Defense World
Wall Street Zen Upgrades Altimmune (NASDAQ:ALT) to “Hold” - Defense World
ALT Hosts Virtual Meeting to Discuss Strategic Developments | ALT Stock News - GuruFocus
Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Northern Trust Corp - Defense World
Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential - MSN
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com
Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On? - Benzinga
Altimmune begins phase 2 trial for AUD treatment By Investing.com - Investing.com South Africa
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluati - GuruFocus
Altimmune (ALT) Begins Phase 2 Trial for Pemvidutide in Treating Alcohol Use Disorder | ALT Stock News - GuruFocus
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder - marketscreener.com
Altimmune begins phase 2 trial for AUD treatment - Investing.com
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times
Breakthrough AUD Drug Enters Phase 2 Trial: New Hope for 28 Million US Patients With Alcohol Use Disorder - Stock Titan
HC Wainwright Has Strong Forecast for Altimmune Q2 Earnings - Defense World
William Blair Estimates Altimmune’s Q2 Earnings (NASDAQ:ALT) - Defense World
Price T Rowe Associates Inc. MD Acquires 4,158 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
B. Riley Issues Positive Estimate for Altimmune Earnings - Defense World
(ALT) Proactive Strategies - news.stocktradersdaily.com
Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway - MSN
Baird Financial Group Inc. Takes Position in Altimmune, Inc. (NASDAQ:ALT) - The AM Reporter
Stifel Financial Corp Sells 4,649 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript - Insider Monkey
Voya Investment Management LLC Decreases Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased - MSN
Piper Sandler maintains Altimmune stock with $25 target - Investing.com Australia
Piper Sandler maintains Altimmune stock with $25 target By Investing.com - Investing.com Nigeria
Altimmune to Participate at Two Upcoming Investor Conferences | - GuruFocus
Altimmune to Participate at Two Upcoming Investor Conferences | ALT Stock News - GuruFocus
Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times
Altimmune Sets Double Conference Appearance: HC Wainwright and Jefferies Healthcare Events Coming Up - Stock Titan
Altimmune’s 2025 Q1 Results Highlight Clinical Progress - TipRanks
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
알티뮨 주식 (ALT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
0.78%
0.23%
자본화:
|
볼륨(24시간):